Triple-negative breast cancer (TNBC), which accounts for approximately 15–20% of all breast cancer cases, is characterized by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.